Objective We related organ-specific autoantibodies, including diabetes-associated antibodies (DAA) and non-diabetes-associated autoantibodies (non-DAA) to systemic cytokines/ chemokines in type 1 and type 2 diabetes.
Introduction
The definition of type 1 diabetes is clinically exclusive, encompassing patients with diabetesassociated autoantibodies (DAA) plus, when diagnosed outside a surveillance program, insulin dependence. Difficulty arises when patients with non-insulin requiring diabetes, clinically like type 2 diabetes, have immuno-genetic characteristics of type 1 diabetes. Such patients have been designated latent autoimmune diabetes in adults (LADA), also called slowly progressive insulin-dependent diabetes (SPIDDM) or type 1.5 diabetes (1). Adultonset autoimmune type 1 diabetes (AID) is characterized by diabetes associated antibodies (DAA), usually autoantibodies against glutamic acid decarboxylase (GADA) (1,2) and encompasses patients with both classic type 1 diabetes, and LADA, of which the latter is most prevalent (2) . Despite having different clinical presentations and phenotype, adults with classic type 1 diabetes and LADA resemble each other as regards their HLA and non-HLA genetic risk, the presence of DAA -predominantly GADA, the frequency of thyroid peroxides autoantibodies (TPOA), frequency of metabolic syndrome and levels in peripheral blood of systemic cytokines (IL-6, TNF-α, IL-1Ra, IL-10), chemokines (CCL2, CCL3, CCL4), adhesion molecules (sE-Selectin, sICAM-1 and sVCAM-1) and peripheral B-lymphocyte subsets (2) (3) (4) (5) (6) (7) (8) . In contrast, patients with type 2 diabetes do not have an HLA genetic association, do not have DAA (1) (2) (3) (4) , have low frequency of TPOA (9) and substantially higher frequency of metabolic syndrome (10) . Similarly, some systemic serum immune mediators are higher in type 2 diabetes than in type 1 diabetes including LADA, e.g. systemic cytokines (IL-6, TNF-α, IL-1Ra, IL-10), chemokines (CCL2, CCL3, CCL4) and adhesion molecules (sE-Selectin, sICAM-1 and sVCAM-1) (11, 12) .
In previous studies we defined a non-random association in type 1 diabetes between adaptive immune changes (the presence and number of DAA) and innate immune changes (the serum levels of systemic cytokines and chemokines) (11) (12) (13) (14) (15) . Here, we extend and expand these 6 studies to include a range of adult-onset clinical diabetes (both forms of type 1 diabetes as well as type 2 diabetes, each analysed for both DAA and non-DAA antibodies as well as a panel of systemic immune mediators: classic type 1 diabetes cytokines, chemokines and adhesion molecules. Our hypothesis is that innate (immune mediators) and adaptive immune reactivity (antibodies) can occur in both the major types of diabetes; adult-onset type 1 diabetes is predominantly associated with adaptive immune changes, while type 2 diabetes is predominantly associated with innate immune changes. Here we show graded differences in adaptive and innate immune changes across the classification of diabetes. 
Research Design and Methods
Patients The Action LADA multicentre study was performed to identify immune and clinical risk factors for adult-onset autoimmune diabetes (AID), including its epidemiology, genetic susceptibility, metabolic characteristics and clinical progression (16) . The study population for the present study consisted of 706 individuals aged from 30 to 70 years; all had been diagnosed with diabetes within 5 years before entering this cross-sectional study from the Action LADA cohort (2) . The cohort consisted of 50 subjects with LADA, 30 with type 1 diabetes and 626 subjects with type 2 diabetes. Patients with other diabetes forms were excluded.
Serum samples were randomly selected with stratification for age and significant serum samples left for analysis. Patients with classic type 1 diabetes were DAA-positive and received insulin treatment shortly after diabetes diagnosis. GADA-positive patients aged from 30 to 70 years who did not use insulin treatment for at least 6 months after diagnosis were termed LADA. The focus of anti-hyperglycaemic medication was on insulin, as the time to start of insulin treatment contributed to the definition of LADA. Antidiabetic medications, other than insulin, were not evaluated. GADA negative and other DAA negative patients who did not use insulin at least for the first year after diagnosis were defined as having type 2 diabetes.
Blood withdrawal from all participants was carried out in the fasting state. The local ethics committees of each study centre approved the study protocol, in accordance with the Declaration of Helsinki. All patients gave written informed consent for the study. Antibody measurements DAA directed against islets (islet cell antibodies, ICA) (13), glutamic acid decarboxylase (GADA), insulinoma-associated antigen (IA2A) and zinc transporter T8 (ZnT8A) were determined (2).
Non-DAA directed against transglutaminase (TGA), parietal cells (PCA) and thyroid (TPOA)
were measured as described. We chose to measure TPOA, PCA and TGA as they are known to be frequently positive in patients with autoimmune diabetes and are well-established gold standards to detect autoimmunity against thyroid, parietal cells and intestinal villous epithelial cells (17) (18) (19) (20) (21) .
In brief, TPOA were examined by B.R.A.H.M.S TPO-Ab RIA (B.R.A.H.M.S. AG) using native thyroid peroxidase as antigen, with results expressed in AU/ml. h and the functional assay sensitivity as 14 AU/ml; the upper limit of detection is 15,000 AU/ml, cut-off for positivity was 60 AU/ml. Tissue transglutaminase antibodies (TGA) were measured by IgA-ELISA (Euroimmun AG);
assay has an upper limit of detection of 200/AU/ml and a cut-off of 20 AU/ml. The intra-and inter-assay variation was 3.5% and 6.8%, respectively.
Systemic cytokines and chemokines
Soluble immune mediators were measured as described (11, 12) . Serum samples were obtained in a standardized form from freshly drawn blood samples from fasting subjects in the morning hours, and were stored at -80°C until the time of the assay without prior thawing. In brief, serum concentrations for sICAM-1, sVCAM-1, sESelectin, CCL2, CCL3 and CCL4 were determined with commercially available multiplexbead technology kits (Fluorokine MAP; R&D Systems, Wiesbaden, Germany). Intra-and inter-assay coefficients of variations were <5% and <11%, respectively. The detection limits of the assays were 13.8 ng/ml for sICAM-1, 69.0 ng/ml for sVCAM-1, 17.1 ng/ml for sE-Selectin, 40.3 pg/ml for CCL2, 2.4 pg/ml for CCL3 and 0.4 pg/ml for CCL4. At least 95% of serum concentrations were above the detection limit for all markers except for CCL3 levels, which were detectable in 72% of all samples. Determinations of immune mediators concentrations lower than the detection limit were assigned a value half of the detection limit as described (11, 22) .
Serum cytokine concentrations of IL-1Ra, IL-6, TNF-α and IL-10 were measured by multiplex-bead technology using commercially available kits (Fluorokine MAP; R&D Systems, Wiesbaden, Germany). The detection limits of the assays were 9.56 pg/ml for IL-1RA, 0.1 pg/ml for IL-6, 0.08 pg/ml for TNF-α and 0.25 pg/ml for IL-10. For cytokine concentrations lower than the detection limit a value half of the detection limit was assigned (IL-6, n=46; IL-1Ra, n=0; TNF-α, n=0). Concentration of cytokine IL-10 was only detectable in 44% of the samples. Immunoassays showed inter-assay variations < 20% and intra-assay variations < 10%.
Statistical methods
We performed the analyses in randomly selected serum samples from participants of Action LADA that were stratified by age. Analyses were performed using SAS (table 2) . Interestingly, no significant association of GADA with immune mediators was observed in this analysis.
As we detected some association of sex, age and BMI with non-DAA concentrations (Suppl. 
Association of high GADA titres with cytokines
We compared adult onset autoimmune diabetes patients with high GADA (>200 U/ml), low GADA (<200 U/ml) and type 2 diabetes patients (all GADA negative). High titre GADA patients had lower IL-6 (p< 0.001), and sE-Selectin (p< 0.01) and a trend toward decreased IL-1Ra (p= 0.052), with a significant trend across the three diabetes cohorts for the former two (p<0.01) indicating an inverse association between an adaptive autoimmune response (GADA) and these systemic immune mediators (Figure 2 ). There were no significant differences for the other cytokines tested, including IL-10, TNF-α, CCL2, CCL3, CCL4, sICAM-1 and sVCAM-1.
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Conclusions
We explored the relationship within the two major types of diabetes between adaptive immunity, represented by both DAA and non-DAA, and innate immunity, represented by 10 systemic immune mediators including cytokines, chemokines and adhesion molecules in the Action LADA cohort. It is well established that type 1 diabetes is associated with DAA irrespective of the clinical phenotype or age at diagnosis. In our study, neither DAA nor non-DAA nor immune mediators could distinguish classic type 1 diabetes from LADA.
As expected, we detected DAA in a large series of over 6,000 adult patients diagnosed with diabetes (2). We selected patients from that series with DAA based on their immediate need for insulin treatment (classic type 1 diabetes) and the lack of that need for at least six months (LADA) plus availability of sufficient sera from the same sample. The majority of these adult-onset cases had a single DAA and the dominant autoantibody was GADA. There was no difference in the frequency or titre of these DAA and the need for insulin therapy or initial clinical phenotype. Type 1 diabetes is associated with other autoimmune diseases including Pernicious Anaemia and Hashimoto's thyroiditis, respectively characterized by parietal cell autoantibodies (PCA) and thyroid peroxidase autoantibodies (TPOA) (25) . The increased frequency of TPOA and PCA are well described in type 1 diabetes but also in LADA patients, e.g. the Italian NIRAD study and the Chinese LADA study (9, (26) (27) (28) . As expected, the frequency of non-DAA here was increased in type 1 diabetes compared with patients with type 2 diabetes irrespective of the initial need for insulin treatment, that is in both classic type 1 diabetes and in LADA; but that increase was due mainly to TPOA and to a lesser extent PCA but not to TGA. Whilst some non-DAA are a feature of type 1 diabetes, these autoantibodies, notably TPOA, were also found in a proportion of patients with type 2 16 diabetes. The percentage of non-DAA positive patients with LADA in our Action LADA cohort was similar to that from other cohorts (9, 28) .
Importantly and unique to this study, we found for autoimmune diabetes, that significantly altered immune mediator levels were nearly all (9/10) negatively correlated with DAA titres and two of four were negatively associated with non-DAA. Serum concentrations of some immune mediators i.e. a cytokine and an adhesion molecule, were overall slightly increased in type 2 diabetes compared to adult onset autoimmune diabetes patients with high GADA titre.
There was a graded increase in IL-6 and sE-Selectin across the main types of diabetes, with This clinical spectrum extends into childhood-onset autoimmune type 1 diabetes in which insulin-dependent patients have the same DAA, though not predominantly GADA, with a stronger HLA genetic susceptibility. That clinical heterogeneity is also reflected in striking variation in insulin secretion, illustrated by C-peptide levels, across the types of diabetes.
Recent large studies have confirmed that there can be substantial serum C-peptide in adultonset type 1 diabetes, suggesting that it is difficult to distinguish some forms of adult-onset type 1 diabetes from type 2 diabetes based on C-peptide alone (23, 24 ). This present study confirms previous studies indicating that LADA and classic type 1 diabetes have, despite clinical differences, a similar cytokine profile with similar levels of serum IL-6 and sESelectin, with each being lower than their corresponding levels in type 2 diabetes. We have now analysed for the first time that relationship in more detail and found that there was an inverse relationship between DAA titres and the levels of four immune mediator molecules such that high titres of one, e.g. ICA, were associated with lower levels of the other e.g.
sVCAM-1, sICAM-1 and TNF-α. It is unclear what pathogenetic mechanism accounts for the 18 relationship between these effector molecules and the two major types of diabetes, but that inverse relationship is even detected within autoimmune diabetes; the group with highest GADA showed decreased IL-6 and sE-Selectin. It will require further study to define the reason for this inverse relationship between adaptive and innate immune changes across a range of adult-onset forms of diabetes.
In summary, we present the first evidence for an effect in both adaptive and innate immunity across type 1 diabetes and type 2 diabetes. Since this graded effect was seen between type 1 diabetes and type 2 diabetes, and even within autoimmune diabetes, the change in immune effectors likely reflects some common pathogenetic mechanism between the major types of the disease. Concentrations (Box and whiskers) of cytokines, chemokines and soluble adhesion molecules in patients with adult autoimmune diabetes (AID) that were GADA high (>200 U/ml) or GADA low (<200 U/ml) and type 2 diabetes patients that were GADA negative. 
Supplement table 1
Data show the number and percentage of patients who are positive for one, two, three or four of the islet directed antibodies measured. LADA and classic type 1 diabetes patients did not differ statistically. ab, antibody; n.s., non-significant
